Standard stents were not engineered for heart attack patients. The webcast of the event will also be archived for a limited time on the Investor Relations section of the Company’s website at. Please allow 10 minutes prior to the call to visit the site and download any necessary audio software.Ī replay of the conference call will be available approximately two hours after completion of the live conference call and will be accessible until 11:59 p.m. A live webcast of the call will be available on the Investor Relations section of the Company’s website at. To access the call, participants should call (877) 842-0788 (United States/Canada) or (317) 468-2947 (International) and request the InspireMD call or provide confirmation code 90920442. InspireMD will host a conference call and webcast to review 12-month MASTER trial follow-up data on Wednesday, Octoat 8:30 a.m. The MASTER trial enrolled a total of 433 patients with STEMI presenting within 12 hours of symptom onset undergoing percutaneous coronary intervention were randomized at 50 sites in 9 countries to the MGuard EPS (n = 217) or commercially available bare metal or drug-eluting stents (n = 216). “These positive results should give clinicians the confidence to use MGuard technology as a first line of defense against distal embolization for their STEMI patients.” Dariusz Dudek, Physician-in-Chief, 2nd Department of Clinical Cardiology and Cardiovascular Interventions at the University Hospital in Krakow. “It is very reassuring to see that the 12-month follow up data is consistent with the acute results presented at TCT last year, especially the data that shows the mortality benefit trend of using this unique technology,” stated Prof. This could be a very important factor when physicians assess clinical treatment options for their patients.” Additionally and importantly, the subset data we released on treatment time from symptom onset to reperfusion revealed that MGuard may increase the therapeutic window for physicians treating STEMI patients. “This data further supports the evidence that positive acute results at the time the patient is treated are associated with improved outcomes at 12 months. Additional 12-month results are available at “The positive follow-up data presented at TCT suggests that our MGuard EPS offers STEMI patients a higher likelihood of survival at 12 months than standard bare metal and drug eluting stents,” stated Alan Milinazzo, President and Chief Executive Officer of InspireMD. These findings are in line with the previously announced 6 month follow-up results showing that all-cause mortality with MGuard EPS was lower than bare metal and drug eluting stents used as a control (0.5% vs. Secondary endpoint clinical outcomes continued to show a lower mortality rate with the MGuard EPS compared to the control (1.0% vs. ST-segment resolution is historically known to be a strong predictor of mortality. The MASTER trial achieved its primary endpoint (p value = 0.008), in complete ST-segment resolution at 60-90 minutes post-procedure. This advanced technology allows the MGuard to specifically address the unmet need for STEMI patients, and save the life of those who suffer from heart attacks. The MGuard utilizes the Company’s proprietary MicroNet™ technology, which is a circular knitted mesh that wraps around the stent to protect patients from plaque debris flowing downstream upon deployment. Jose Henriques will lead the symposium and will be joined by a panel of medical experts. Results from the trial were presented at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in San Francisco earlier today.Īdditionally, the Company will be holding an evening symposium tomorrow, October 30 th, starting at 6:30 pm PT. (“InspireMD” or the “Company”) (NYSE MKT: NSPR), a leader in embolic protection stents, today announced new 12-month results from the MASTER ( MGuard for Acute ST Elevation Reperfusion) trial demonstrating that the MGuard outperformed bare metal and drug eluting stents in all-cause mortality in ST segment elevation myocardial infarction (STEMI) patients. InspireMD’s MGuard Stent Shows Lower Mortality Rate in STEMI Patients at Twelve Months Compared to Control GroupĬompany to Host Conference Call Tomorrow at 5:30 a.m.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |